126-18-1
中文名稱
菝葜
英文名稱
SMILAGENIN
CAS
126-18-1
分子式
C27H44O3
分子量
416.64
MOL 文件
126-18-1.mol
更新日期
2024/11/06 17:54:41
126-18-1 結(jié)構(gòu)式
基本信息
中文別名
菝葜菝葜配質(zhì)
菝葜配基
異菝葜皂甙
英文別名
Nsc93747SMILAGENIN
ESMILAGENIN
ISOSARSAPOGENIN
Smilax china L
ISOSARSAPOGENINE
ISOSARSASAPOGENIN
SMILAGENIN USP/EP/BP
(25r)-spirostan-3β-ol
(25R)-SPIROSTAN-3BETA-OL
所屬類別
生物化工：中草藥成分物理化學(xué)性質(zhì)
熔點(diǎn)~185 °C
比旋光度D25 -69° (c = 0.5 in chloroform)
沸點(diǎn)474.91°C (rough estimate)
密度1.0362 (rough estimate)
折射率1.4700 (estimate)
儲(chǔ)存條件-20°C儲(chǔ)存
溶解度Ethanol: ≥ 10 mg/mL (24.00 mM); DMSO: < 1 mg/mL (insoluble or slightly soluble)
酸度系數(shù)(pKa)15.14±0.70(Predicted)
形態(tài)Solid
顏色White to off-white
菝葜價(jià)格(試劑級(jí))
| 報(bào)價(jià)日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱 | CAS號(hào) | 包裝 | 價(jià)格 |
| 2024/11/08 | HY-106353 | 菝葜 Smilagenin | 126-18-1 | 5mg | 800元 |
| 2024/11/08 | HY-106353 | 菝葜 Smilagenin | 126-18-1 | 10mg | 1200元 |
| 2024/11/08 | HY-106353 | 菝葜 Smilagenin | 126-18-1 | 50mg | 3500元 |
常見問題列表
生物活性
Smilagenin (SMI) 是一種脂溶性小分子甾體皂苷元，來自知母 Rhizoma anemarrhenae 和天竺葵 Radix asparagi，廣泛用于慢性神經(jīng)退行性疾病的研究。Smilagenin (SMI) 通過增加毒蕈堿受體亞型 1 (M1)-受體的的密度來改善老年大鼠的記憶。
Smilagenin (SMI) 通過刺激腦源性神經(jīng)營(yíng)養(yǎng)因子的基因表達(dá)減弱 Aβ (25-35) 誘導(dǎo)的神經(jīng)變性，可用于 AD 的研究。靶點(diǎn)
|
Human Endogenous Metabolite
|
體外研究
Smilagenin (10 μM; 24 hours) increases SH-SY5Y cell survival compared with Aβ(25-35) intoxicated cells. Smilagenin (10 μM; 24 hours) increases neurotrophic factor (GDNF) and neurotrophic factor (BDNF) mRNA level by promoting CREB phosphorylation in 1-methyl-4-phenylpyridimium (MPP + ) treated SH-SY5Y cells.
Cell Viability Assay
| Cell Line: | SH-SY5Y cells |
| Concentration: | 10 μM |
| Incubation Time: | 24 hours |
| Result: | Elevated the SH-SY5Y cell viability. |
RT-PCR
| Cell Line: | SH-SY5Y cells |
| Concentration: | 10 μM |
| Incubation Time: | 24 hours |
| Result: | Increased GDNF and BDNF transcription. |
體內(nèi)研究
Smilagenin (intragastric administration; 10 or 26 mg/kg, once daily; 60 days) prevents the impairment of dopaminergic neurons in chronic MPTP/probenecid-induced mouse model.
| Animal Model: | MPTP/probenecid-induced mouse model |
| Dosage: | 10 or 26 mg/kg |
| Administration: | Intragastric administration; 10 or 26 mg/kg; once daily; 60 days |
| Result: | Ameliorated locomotor ability of MPTP/probenecid-lesioned mice. |